Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Thomas Huisman

Urology Brandywine, MD Medical Doctor

NPI 1982661211 CMS profile 90349

7704 Matapeake Business Dr, Suite 310, Brandywine, MD 20613

Open in the dashboard

General payments

$3,702

177 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$361,838

7 holdings reported · through program year 2024

Through program year 2024, Thomas Huisman of Brandywine, MD is reported in the CMS Open Payments database as having received $3,702 across 177 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $361,838 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $18 1
2023 General $288 10
2022 General $452 22
2021 General $1,060 61
2020 General $747 17
2019 General $1,136 66
2024 Ownership $80,182 2
2023 Ownership $78,612 1
2022 Ownership $37,951 1
2021 Ownership $35,240 1
2020 Ownership $90,359 1
2019 Ownership $39,494 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Huisman
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Thomas Huisman were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Thomas Huisman Urology median Middle half National median
2019 $1,136 $480 $147–$1,201 $163
2020 $747 $246 $87–$645 $114
2021 $1,060 $358 $111–$1,000 $132
2022 $452 $476 $143–$1,263 $149
2023 $288 $560 $168–$1,461 $160
2024 $18 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Contura, Inc. $444 5 payments
  2. Astellas Pharma US Inc $368 20 payments
  3. Janssen Biotech, Inc. $359 20 payments
  4. Endo Pharmaceuticals Inc. $315 14 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $310 15 payments
  6. AbbVie, Inc. $193 14 payments
  7. Pfizer Inc. $185 12 payments
  8. Allergan Inc. $164 11 payments
  9. Ferring Pharmaceuticals Inc. $160 11 payments
  10. Amgen Inc. $124 6 payments
  11. Other $1,079 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,530 176 payments
  2. Travel and Lodging $172 1 payment
Products named General payments · program years 2019–2024
  1. Bulkamid $444 5 payments
  2. ERLEADA $336 19 payments
  3. XTANDI $280 16 payments
  4. XIAFLEX $278 12 payments
  5. MYRBETRIQ $272 16 payments
  6. AVEED $234 13 payments
  7. Xofigo $192 9 payments
  8. EDEX $181 10 payments
  9. Nubeqa $181 9 payments
  10. LUPRON DEPOT $180 13 payments
  11. Other $1,827 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record